| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-259893 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| 27497027 |
Zevalin® (ibritumomab tiuxetan) is a radioactive drug product, which is the combination of a β-emitting isotope, 90Y, linked to the anti-CD20 monoclonal antibody (mAb), rituximab. It has demonstrated therapeutic efficacy with durable responses and allows delivery of ionizing radiation directly to the tumor site, while minimizing toxicity to normal tissue. Ibritumomab tiuxetan is indicated for treatment of patients with relapsed or refractory low-grade, follicular NHL |
|
3.0
ibritumomab tiuxetan
binding